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Introduction {#s1}
============

Hepatocellular carcinoma (HCC), which is the sixth common neoplasm, ranks the third in cancer mortality in the world [@pone.0107941-Ferlay1]. 80% of the HCC are mainly found in eastern Asia and sub-Saharan Africa [@pone.0107941-ElSerag1]. HCC is a complex process mediated by multiple genes. The risk factors for the development of HCC, which interact and cooperate with each other, could increase the probability of HCC tumorigenesis. Most people suffering from HCC will die within one year after its detection [@pone.0107941-Zhang1]. One reason for the high mortality can in part be attributed to extrahepatic metastasis [@pone.0107941-Kang1] and the bottleneck in treatment of HCC is to prevent extrahepatic metastasis. The understanding of the gene transcription profiling underlying HCC metastasis will provide us new theoretical basis for HCC diagnosis and treatment.

Glycosylation, which can be found in a variety of physiological and pathological events, is one of the most important kinds of posttranslational modifications. More than 50% of proteins in nature are presumed to have undergone glycosylation [@pone.0107941-Apweiler1]. These glycans not only alter the structures and functions of glycoproteins, but also are crucial for cell adhesion and cellular signal transduction. Other than that, aberrant glycosylation also plays a key role in the underlying mechanism of a variety of diseases [@pone.0107941-Taniguchi1]. Glycans are formed by the catalytic activity of enzymes such as glycosyltransferases and glycosidases. The alterations in transcription and translation levels of enzymes are related to corresponding changes in the glycan branched structures. Currently, studies of the aberrant glycosylation in HCC have been paid much attention and certain achievements have been made. *mgat3* and *mgat5* were proved to be over-expressed in human HCC cell lines, knockdown of *mgat3* could promote cells invasion and increase the resistance to 5-fluorouracil in vitro [@pone.0107941-Guo1]. However, the silence of *mgat5* in cells could inhibit invasion and increase sensitivity to 5-fluorouracil in vitro. *mgat4a* was vital to tumor migration and metastasis through altering the glycosylation of CD147 [@pone.0107941-Fan1]. It was also reported that transcription levels of *mgat4b*, and *mgat5* were increased in mice with HCC [@pone.0107941-Blomme1]. Recently, further analysis revealed that *mgat5* could partially decrease cell adhesion and promote cell proliferation through RPTPκ [@pone.0107941-Wang1].

In this study, we obtained and identified the transcriptional profiling of glycogenes in human HCC cell lines with or without metastasis potential and orthotopic xenograft tumors by PCR Array and qRT-PCR. The differentially transcribed glycogenes were classified and described by *K*-mean clustering and GO analysis, respectively. The possible regulatory network of them was built by the IPA. Furthermore, the differently transcribed glycogenges were validated in clinical cancer specimens by PCR Array. This work might provide the novel potential drug targets and the potential biological markers of HCC.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Access to human tissues complied with both Chinese laws and the guidelines of the Ethics Committee and this study was approved by the Research Ethics Committee of Zhongshan Hospital and First Affiliated Hospital of Guangxi Medical University. All participants have given written informed consent.

Cell Culture {#s2b}
------------

The Human HCC cell lines with different metastatic potentials (MHCC97L, MHCC97H and HCCLM3) have the same genetic background and were established in our Liver Cancer Institute [@pone.0107941-Li1]--[@pone.0107941-Li3]. All of them were cultured in Dulbecco's modified Eagle's (DMEM) medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA). Hep3B, the non-metastatic HCC cell line (ATCC number HB-8065), was generously provided by Cornell University and was cultured in minimum essential medium (MEM) medium (Gibco, USA) supplemented with 10% FBS (Gibco, USA). All of these cells were incubated at 37°C with a 5% CO~2~ in air atmosphere.

HCC orthotopic xenograft tumor model in nude mice {#s2c}
-------------------------------------------------

The male BALB/C nude mice (5 to 6-week-old) we obtained were from Shanghai Institute of Materia Medica (Chinese Academy of Sciences, Shanghai, China). The orthotopic xenograft tumor models were established as described previously [@pone.0107941-Sun1]--[@pone.0107941-Wang2]. Simply, 1×10^7^ Hep3B, MHCC97L, MHCC97H or HCCLM3 cell lines were injected subcutaneously into the upper left flank region of nude mice, respectively. After tumor formation, the tumors were cut into 2 mm×2 mm×2 mm sized pieces. Nude mice that were anaesthetized with pentobarbital 45 mg/kg by intraperitoneal injection after regular disinfection were dissected and then the tumor tissue lumps were implanted into livers of nude mice. The mice were slaughtered at the 35th day after tumor implantation and the orthotopic xenograft tumors were immediately placed in liquid nitrogen. All of the in vivo experiments carried out were strictly complied with the protocol which was approved by the Shanghai Medical Experimental Animal Care Committee (Permit Number: 2009-0082).

Clinical cancer specimens {#s2d}
-------------------------

Fifteen HCC patients under-going resection in 2012 in Zhongshan Hospital, Fudan University (Shanghai, China) and First Affiliated Hospital of Guangxi Medical University (Nanning, China) were enrolled in this study, including ten patients with non-metastatic HCC and five patients with metastatic HCC. All the tissue samples collected from the patients were performed to qRT-PCR analysis. The detailed information of these fifteen patients was described in [Table S1](#pone.0107941.s001){ref-type="supplementary-material"}.

Human Glycosylation PCR Array and qRT-PCR {#s2e}
-----------------------------------------

Total RNA was harvested from cultured cells, orthotopic xenograft tumors and clinical cancer specimens with TRIzol (Invitrogen) and purified with the RNeasy MinElute Cleanup Kit (Qiagen) according to the manufacturer\'s instruction. After quantification using a Nanodrop spectrophotometer, 10 µg total RNA was reversed transcribed into cDNA using the Revert Aid First Strand cDNA Synthesis Kits (Fermentas), respectively. Besides, cDNA prepared respectively with Super Array PCR master mix (Cat. No. PA-112) was needed in order to perform PCR Array.

The Human Glycosylation RT^2^ Profiler PCR Array, including 84 key genes encoding glycan processing enzymes i.e. glycosyltransferase and glycosidase for several important sugars: galactose, glucose, mannose, N-acetylgalactosamine, N-acetylglucosamine, fucose and sialic acid, was designed and produced by the Qiagen company (German).

The PCR Array and qRT-PCR were performed on IQ5 machine (Bio-Rad) and the PCR cycling condition was set as follows: 95°C for 5 min, 40 cycles of 95°C for 15 s, 60°C for 15 s and 72°C for 20 s. Each test was run three times and the mean was taken to eradicate any discrepancies.

The used primer sequences in qRT-PCR were summarized in [Table 1](#pone-0107941-t001){ref-type="table"}.

10.1371/journal.pone.0107941.t001

###### Sequences of qRT-PCR primers.

![](pone.0107941.t001){#pone-0107941-t001-1}

  Glycogene             Primer Sequence
  ----------- -----------------------------------
  *c1galt1*      F: 5′-ATGAGTGGAGGAGCAGGATA-3′
                 R: 5′-TCTGGCACAAAGGGATGAA-3′
  *galnt3*        F: 5′-CTGCCTCTCCAGGCAACG-3′
                 R: 5′-GTAGTACCTGGCGGGTGGG-3′
  *gcnt3*       F: 5′-AGATGTTGAATGGGAGGAATAG-3′
               R: 5′-TGTTGGTTAGGTGTAATGTGTCTC-3′
  *man1a1*     F: 5′-CTCTCAGCCTACTATCTGTCTGG-3′
                R: 5′-CAGTTCCTTCCAATACCACTTT-3′
  *mgat4a*      F: 5′-GCAACGGAAGAACAGGAGTTTC-3′
                R: 5′-AGGTTGGCTACAACACCATGT-3′
  *mgat5*         F: 5′-GCTGCCCCTGTAGGAGAC-3′
                 R: 5′-GAATCAAGGACTCGGAGCAT-3′
  *mgat5b*       F: 5′-ATGAGTGGAGGAGCAGGATA-3′
                 R: 5′-TCTGGCACAAAGGGATGAA-3′
  *st3gal1*      F: 5′-CACGAATGGCGTTGGTCTAC-3′
                 R: 5′-CTCAATCAAAAGGGATGGCA-3′
  *β-Actin*     F: 5′-CATGTACGTTGCTATCCAGGC-3′
                R: 5′-CTCCTTAATGTCACGCACGAT-3′

Statistical analysis and database searching {#s2f}
-------------------------------------------

Take advantage of the Ct obtained from PCR-Array, the MeV 4.8.1 was used to map the hierarchical clustering of all the glycogenes in the PCR Array, the differentially transcribed glycogenes generated and altered N-linked glycans, O-linked glycans and glycosphingolipids, respectively.

The fold change was normalized to the expression of the housekeeping gene, *β-Actin,* and was calculated respectively for each cell using 2^−ΔΔCt^, where ΔΔCt = (Ct target gene-*β-Actin*) MHCC97L/MHCC97H/HCCLM3-(Ct target gene-*β-Actin*) Hep3B. Glycogene with differences greater than 2-fold (P≤0.05) was considered as the differentially transcribed glycogenes and they were divided into six clusters by a *K-*means approach, which is a kind of clustering algorithm for grouping genes or proteins with a similar expression pattern [@pone.0107941-Wang2], [@pone.0107941-Yu1] and the GO was used to describe. IPA (Ingenuity System Inc, USA) is a proof of knowledge based comprehensive software of data analysis that can help researchers model, analyze, and understand the complex biological and chemical systems in life science research [@pone.0107941-Nehme1], [@pone.0107941-Lv1]. The differentially transcribed glycogenes were uploaded to the database to explore regulatory network. In the analysis of validation in clinical cancer specimens, the housekeeping gene *β-Actin* was as the reference and the relative expressions value were expressed by ΔCt = Ct target gene-*β-Actin*, which means that the higher value of ΔCt of the glycogene, the lower its transcription level.

Results {#s3}
=======

The transcriptional profiling of glycogenes {#s3a}
-------------------------------------------

The transcriptional profiling of the 84 glycogenes was obtained by the Human Glycosylation RT^2^ Profiler PCR Array and was used to produce a hierarchical clustering scheme ([Figure. 1A](#pone-0107941-g001){ref-type="fig"}). A total of thirty-three glycogenes were differentially transcribed. Among them, sixteen glycogenes generated and altered mature N-linked glycans, eighteen glycogenes were concerned in the synthesis and processing of O-linked glycans, three glycogenes acted on glycosphingolipids ([Figure 1B--D](#pone-0107941-g001){ref-type="fig"}). Double counting did occur among four glycogenes *b3gnt3*, *hexa*, *st3gal1*, *st8sia3*, which took part in the synthesis of two kinds of glycans. A total of eighteen mRNA, such as *mgat5*, *st3gal1*, *st8sia4*, were up-regulated in the HCC cell lines with different metastatic potentials (MHCC97L, MHCC97H and HCCLM3) compared with the non-metastatic HCC cell line Hep3B, while fifteen mRNA like *c1galt1*, *gcent4*, *man1a1* were down-regulated ([Table 2](#pone-0107941-t002){ref-type="table"} and [3](#pone-0107941-t003){ref-type="table"}). *st3gal1* could mediate the sialylation of T antigen and the increase of *st3gal1* expression had been shown to be one of the major mechanisms responsible for the sialylation of T antigen [@pone.0107941-Brockhausen1]. Sialyl-T antigen was tumor-associated carbohydrate antigen whose expression was largely increased in some types of cancers and associated with poor prognosis [@pone.0107941-Videira1]. Polysialic acid was a carbohydrate composed of a linear homopolymer of α2, 8-linked sialic acid residues and was with a large amount of negative charge. The presence of polysialic acid attenuates the adhesive property of neural cell adhesion molecule and increases cellular motility. *st8sia4* was one of the α2, 8-sialyltransferases which could add oligosialic and polysialic acid into various sialylated N-acetyllactosaminyl oligosaccharides [@pone.0107941-Tanaka1]--[@pone.0107941-Angata1]. Amounts of β-1, 6-GlcNAc branched N-Glycan were commonly increased in malignancies and correlated with disease progression. *mgat5* was required in the biosynthesis of β-1, 6-GlcNAc-branched N-linked glycans attaching to cell surface and secreted glycoproteins.

![Hierarchical clustering.\
(A) Hierarchical clustering of 84 glycogenes. Each row represented a single gene; each column represented a cell line. The expression levels of glycogenes, which were the average value of three test results, were shown by the color scale: red represents a target gene with high Ct value while green represents a target gene with low Ct value. (B) Hierarchical clustering of 3 glycogenes acted on glycosphingolipids. (C) Hierarchical clustering of 16 glycogenes generated and altered mature N-linked glycans. (D) Hierarchical clustering of 18 glycogenes generated and altered mature O-linked glycans.](pone.0107941.g001){#pone-0107941-g001}

10.1371/journal.pone.0107941.t002

###### Up-regulated glycogenes in HCC cell lines with different metastatic potentials.

![](pone.0107941.t002){#pone-0107941-t002-2}

             GeneSymbol    UniGene ID   GeneBank ID              Functional GeneGrouping              Fold Change(MHCC97L/Hep3B)   Fold Change(MHCC97H/Hep3B)   FoldChange(HCC LM3/Hep3B)
  -------- -------------- ------------ ------------- ----------------------------------------------- ---------------------------- ---------------------------- ---------------------------
  **1**       *b3gnt3*     Hs.657825     NM_014256          N-acetylglucosaminyltransferases                    14.32                        10.34                        10.13
  **2**      *b4galt5*     Hs.370487     NM_004776               Galactosyltransferases                          2.07                         2.25                        2.99
  **3**       *edem1*      Hs.224616     NM_014674                    Mannosidases                              14.12                         3.05                        2.31
  **4**       *edem2*      Hs.356273     NM_018217                    Mannosidases                               2.68                         2.48                        2.71
  **5**      *galnt11*     Hs.647109     NM_022087         N-acetylgalactosaminyltransferases                   1.80\*                        2.14                        2.39
  **6**       *galnt4*      Hs.25130     NM_003774         N-acetylgalactosaminyltransferases                    3.25                         2.03                        2.16
  **7**       *galnt7*     Hs.548088     NM_017423         N-acetylgalactosaminyltransferases                    2.38                         3.48                        5.24
  **8**       *gcnt3*      Hs.194710     NM_004751          N-acetylglucosaminyltransferases                    47.18                        41.36                        28.84
  **9**        *hexa*      Hs.604479     NM_000520    Galactosides & Glucosidases & Hexosaminidases              2.50                         2.36                        2.41
  **10**      *man1b1*     Hs.279881     NM_016219                    Mannosidases                               2.27                        1.73\*                       2.33
  **11**      *man1c1*     Hs.197043     NM_020379                    Mannosidases                              30.06                        11.55                        11.47
  **12**      *mgat5*      Hs.651869     NM_002410          N-acetylglucosaminyltransferases                     7.94                         4.69                        9.85
  **13**      *mgat5b*     Hs.144531     NM_144677          N-acetylglucosaminyltransferases                    240.52                       71.51                       292.04
  **14**       *ogt*       Hs.405410     NM_181673          N-acetylglucosaminyltransferases                     3.97                         2.51                        4.00
  **15**     *pomgnt1*     Hs.525134     NM_017739          N-acetylglucosaminyltransferases                     2.25                       1.92\*\*                      2.30
  **16**     *st3gal1*     Hs.374257     NM_173344                 Sialyltransferases                           117.78                       91.77                       166.57
  **17**    *st6galnac1*   Hs.105352     NM_018414                 Sialyltransferases                           280.14                       404.50                      119.43
  **18**     *st8sia4*     Hs.308628     NM_175052                 Sialyltransferases                           288.02                       42.52                        81.01

Note: Fold Change\>2, P≤0.5; \*: Fold Change\<2, P≤0.5; \*\*: Fold Change\<2, P≥0.5.

10.1371/journal.pone.0107941.t003

###### Down-regulated glycogenes in HCC cell lines with different metastatic potentials.

![](pone.0107941.t003){#pone-0107941-t003-3}

            GeneSymbol   UniGeneID   GeneBankID        Functional Gene Grouping        Fold Change(MHCC97L/Hep3B)   Fold Change(MHCC97H/Hep3B)   Fold Change(HCCLM3/Hep3B)
  -------- ------------ ----------- ------------ ------------------------------------ ---------------------------- ---------------------------- ---------------------------
  **1**      *a4gnt*     Hs.278960   NM_016161     N-acetylglucosaminyltransferases               0.20                         0.09                        0.17
  **2**     *c1galt1*    Hs.592180   NM_020156          Galactosyltransferases                    0.33                         0.45                        0.48
  **3**      *galnt1*    Hs.514806   NM_020474    N-acetylgalactosaminyltransferases              0.38                         0.36                        0.39
  **4**     *galnt12*    Hs.47099    NM_024642    N-acetylgalactosaminyltransferases              0.01                         0.00                        0.01
  **5**     *galnt13*    Hs.470277   NM_052917    N-acetylgalactosaminyltransferases              0.00                         0.00                        0.01
  **6**      *galnt3*    Hs.170986   NM_004482    N-acetylgalactosaminyltransferases              0.01                         0.01                        0.00
  **7**     *galntl1*    Hs.21035    NM_020692    N-acetylgalactosaminyltransferases              0.22                         0.03                        0.04
  **8**      *gant4*     Hs.272404   NM_016591     N-acetylglucosaminyltransferases               0.06                         0.15                        0.18
  **9**      *man1a1*    Hs.102788   NM_005907               Mannosidases                         0.14                         0.09                        0.12
  **10**     *man2a2*    Hs.116459   NM_006122               Mannosidases                        0.63\*                        0.45                        0.27
  **11**     *man2b1*    Hs.356769   NM_000528               Mannosidases                         0.19                         0.15                        0.11
  **12**     *mgat1*     Hs.519818   NM_002406     N-acetylglucosaminyltransferases              0.85\*                        0.49                        0.50
  **13**     *mgat4a*    Hs.177576   NM_012214     N-acetylglucosaminyltransferases               0.01                         0.01                        0.00
  **14**    *st8sia3*    Hs.23172    NM_015879            Sialyltransferases                      0.01                         0.01                        0.01
  **15**     *uggt2*     Hs.193226   NM_020121           Glucosyltransferases                     0.34                         0.33                        0.36

Note: Fold Change\<0.5, P≤0.5; \*Fold Change\>0.5, P≤0.5.

Identification in human HCC cell lines and their orthotopic xenograft tumors by qRT-PCR {#s3b}
---------------------------------------------------------------------------------------

Seven glycogenes: *c1galt1*, *galnt3*, *gcnt3*, *man1a1*, *mgat4a*, *mgat5*, *mgat5b*, were selected to identify the results of the PCR Array by qRT-PCR in human HCC cell lines (Hep3B, MHCC97L, MHCC97H, HCCLM3) and their orthotopic xenograft tumors. The housekeeping gene *β-Actin* was as the reference and normalized the obtained fold changes of differential glycogenes. The results of the human HCC cell lines were shown in [Figure 2A, C, E, G, I, K, M](#pone-0107941-g002){ref-type="fig"}, meanwhile the results from the orthotopic xenograft tumors were in [Figure 2B, D, F, H, J, L, N](#pone-0107941-g002){ref-type="fig"}. *c1ganlt1*, *man1a1*, *mgat4a*, *galnt3* were all down-regulated whereas *gcnt3*, *mgat5*, *mgat5b* were all obviously up-regulated, almost all the transcription levels of the glycogenes had significant difference. These results supported the transcriptional profiling from the PCR Array.

![Identification of the differentially transcribed glycogenes in human HCC cell lines and their orthotopic xenograft tumors by qRT-PCR.\
A, C, E, G, I, K and M were the HCC cell lines with different metastatic potentials (MHCC97L, MHCC97H, HCCLM3) with the comparison to the no-metastatic Hep3B cell line, respectively. B, D, F, H, J, L and N were the orthotopic xenograft tumors of the HCC cell lines MHCC97L, MHCC97H, HCCLM3 comparison to the orthotopic xenograft tumor of the Hep3B cell line. The expression of these glycogenes were normalized against endogenous mRNA of the housekeeping gene, *β-Actin*.](pone.0107941.g002){#pone-0107941-g002}

*K*-mean clustering and GO analysis {#s3c}
-----------------------------------

The thirty-three differentially transcribed glycogenes were classified in six clusters according to their trends by *K*-means clustering ([Figure 3](#pone-0107941-g003){ref-type="fig"}, [Table S2](#pone.0107941.s002){ref-type="supplementary-material"}). Among these, only *b4galt5*, *galnt7*, *galnt11* were up-regulated gradually while *man2a2*, *mgat1* were down-regulated step by step, which implied that changes of diverse glycogenes transcription had little related with the level of metastatic potentials. GO teams were used to describe three attributes of the differentially transcribed glycogenes ([Figure 4](#pone-0107941-g004){ref-type="fig"}). The differentially transcribed glycogenes were closely related with some types of biological process, such as protein amino acid glycosylation, glycoprotein metabolic process, glycoprotein biosynthetic process. The subcellular distributions of these glycogenes were enriched in golgi apparatus, golgi membrane, and so on. They were associated with molecular functions, like acetylglucosaminyltransferase activity, mannosidase activity, polypeptide N-acetylgalactosaminyltransferase activity.

![*K-*means clustering of differentially transcribed glycogenes.\
Each line represented one differentially transcribed glycogene, the shape of lines displayed the expression trend of the differentially transcribed glycogenes in the no-metastatic HCC cell line Hep3B and the HCC cell lines with different metastatic potentials (MHCC97L, MHCC97H and HCCLM3).](pone.0107941.g003){#pone-0107941-g003}

![GO analysis of differentially transcribed glycogenes.\
The differentially transcribed glycogenes were described in 3 categories: biological process, subcellular location, molecular function. GO teams were used to describe three as their attributes of the differentially transcribed glycogenes.](pone.0107941.g004){#pone-0107941-g004}

Regulatory network by IPA {#s3d}
-------------------------

All of the thirty-three differentially transcribed glycogenes were uploaded to the database to analyze upstream regulatory events and build the possible regulatory network by the IPA ([Figure 5](#pone-0107941-g005){ref-type="fig"}). The molecule type, p-value of overlap and target molecules of the transcription regulators in the regulatory network were described and listed in [Table 4](#pone-0107941-t004){ref-type="table"}. We found that a transcription regulator may control more than one glycogene, such as SIRT1 which can act on *edem1* and *mgat1*. At the same time, it was not difficult to detect that a glycogene may be simultaneously affected by two or more transcription regulators. Instances were described as following: *galnt11* was direct regulated by CLOCK, meanwhile it was indirectly regulated by CCND1. Moreover, *edem1* was directly influenced by XBP1, KCNIP3 and SIRT1, in the meantime, it was indirectly influenced by TMB1M6, IDH1, BAK1. As expected, results showed that the different transcription regulators tended to have different degree of regulation on glycogene expressions and these influences could be measured by the p-value of overlap. The smaller p-value of overlap there was, the greater influence of the regulation there was. For a given glycogene, which of the transcription regulator(s) had more influence could be discriminated by the p-value of overlap. Like *edem1* as a glycogene was influenced by XBP1, SIRT1, TMBIM6, IDH1, BAK1, KCNIP3, nevertheless, KCNIP3 and TMBIM6 play much more important roles. For the seventeen glycogenes in the regulatory network, NCF4, SDC1, SIRT1, CLOCK, TMBIM6 had smaller p-values and it suggested that they may play more important roles in the transcriptional regulation of the differentially transcribed glycogenes.

![Regulatory network of glycogenes by IPA.\
The network of glycogenes was derived from the thirty-three differentially transcribed glycogenes. The grey ones represented they were included in the differentially transcribed glycogenes whereas the white ones represented they were not. There were six types of relationship in the network, A: activation, E: expression, M: modification, PD: protein-DNA interaction, PP: protein-protein interaction, T: transcription. Full lines meant a direct action between two nodes, while the dotted lines meant an indirect relationship between two nodes.](pone.0107941.g005){#pone-0107941-g005}

10.1371/journal.pone.0107941.t004

###### Upstream regulators and target molecules in the regulatory network.

![](pone.0107941.t004){#pone-0107941-t004-4}

  Upstream Regulator    EntrezID        Molecule Type        p-value of overlap   Target molecules in dataset
  -------------------- ---------- ------------------------- -------------------- -----------------------------
  ACSL5                  51703             enzyme                  0.0246                  *galnt13*
  ADCYAP1                 116               other                  0.0467             *galnt7*, *man1a1*
  AIRE                    326      transcription regulator         0.0023              *mgat1*, *mgat5*
  BAK1                    578               other                  0.0416                   *edem1*
  CCND1                   595               other                  0.0418           *galnt11*, *st6galnac1*
  CLOCK                   9575     transcription regulator         0.0186            *galnt11*, *pomgnt1*
  ETS1                    2113     transcription regulator         0.0352             *b4galt5*, *mgat5*
  ETV4                    2118     transcription regulator         0.0416                  *b4galt5*
  HIST1H1A                3024              other                  0.0003         *b4galt5*, *man2b1*, *ogt*
  HIST1H1T                3010              other                  0.0003         *b4galt5*, *man2b1*, *ogt*
  IDH1                    3417             enzyme                  0.0416                   *edem1*
  KCNIP3                 30818     transcription regulator         0.0232                   *edem1*
  NCF4                    4689             enzyme                  0.0146                  *st3gal1*
  SDC1                    6382             enzyme                  0.0117                  *galnt3*
  SIRT1                  23411     transcription regulator         0.0125              *edem1*, *mgat1*
  STAT5B                  6777     transcription regulator         0.0229              *hexa*, *st8sia4*
  TFEB                    7942     transcription regulator         0.0445                   *hexa*
  TMBIM6                  7009              other                  0.0189                   *edem1*
  XBP1                    7494     transcription regulator         0.0340              *edem1*, *edem2*

Validation in clinical cancer specimens by qRT-PCR {#s3e}
--------------------------------------------------

Four differentially transcribed glycogenes, including *galnt3*, *gcnt3*, *man1a1*, *mgat5b* were selected to detect the expressions in clinical cancer specimens and their results were shown in [Figure 6](#pone-0107941-g006){ref-type="fig"}. Although the transcription levels of *galnt3* and *man1a1* in metastatic HCC clinical cancer specimens were lower than in the non-metastatic ones, there were no significant differences (P = 0.246, P = 0.108, respectively). While the divergent trends of *gcnt3* and *mgat5b* between non-metastatic and metastatic HCC clinical cancer specimens were statistically significant (P = 0.002, P = 0.04, respectively) and they were all up-regulated in metastatic HCC clinical cancer specimens, which trends were as same as in human HCC cell lines and their orthotopic xenograft tumors. *gcnt3* (glucosaminyl (N-acetyl) transferase 3, mucin type) is required to form GlcNAcβ1→6Gal/GalNAc ([Figure 6E](#pone-0107941-g006){ref-type="fig"}) [@pone.0107941-GonzalezVallinas1] and *mgat5b* (mannosyl (α-1,6-)-glycoprotein β-1,6-N-acetyl-glucosaminyltransferase, isozyme B) acts on the GlcNAc β1,2-Manα1-Ser/Thr moiety, forms a 2,6-branched structure in brain O-mannosyl glycan ([Figure 6F](#pone-0107941-g006){ref-type="fig"}) [@pone.0107941-Inamori1].

![Validation in non-metastatic and metastatic tissue samples by qRT-PCR.\
A, B, C, D were the transcription levels of *galnt3*, *gcnt3*, *man1a1*, *mgat5b*, respectively. The housekeeping gene, *β-Actin* was used to normalize the expression levels in the subsequent quantitative analyses, and the higher value of ΔCt of the glycogene, the lower its transcription level. E, *gcnt3* involved in the glycan biosynthetic pathways. F, *mgat5b was* correlated with the pathway of glycan biosynthetic.](pone.0107941.g006){#pone-0107941-g006}

Discussion {#s4}
==========

A growing number of researches indicated that the structural modifications of cell membrane glycans had correlation with disease progression, metastasis, and poor prognosis [@pone.0107941-Yamamoto1], [@pone.0107941-Handerson1]. Essentially, cancer could be regarded as a molecular disease of cell membrane glycans because cancer cells were characterized by aberrant glycosylation of the surface membrane [@pone.0107941-Hakomori1]. Abnormal glycosylation was also highly associated with HCC progression. The alterations of glycan branched structures of glycoproteins, such as GlcNAc-branched N--glycans, sialic acid and core fucosylation, were demonstrated to be highly expressed in HCC and these changes were closely related to the transcriptional and translational levels of the glycogenes [@pone.0107941-Ang1]--[@pone.0107941-Pettersen1]. It was generally known that AFP-L3, which was the LCA-bound fraction of AFP, as a new generation of tumor marker for HCC had been widely used in clinic. It had been reported that malignant liver cells produce AFP-L3, even when HCC was at its early stage [@pone.0107941-Pettersen1]. In the meantime, *fut8* was known to be a key enzyme of fucosylation and it had been implicated in the production of AFP-L3 [@pone.0107941-Li4], [@pone.0107941-Tian1]. This example suggested that some abnormal glycosylation and the differentially transcribed glycogenes might be potential markers of biologic malignancy of HCC and maybe they could be used for identifying subtypes of HCC and elevating the possibility of individual treatment, hence the further research was needed.

In current study, we obtained and validated the transcriptional profiling of glycogenes. This was the first study to select the transcriptional profiling of glycogenes associated with HCC metastasis by PCR Array and it was a comprehensive analysis of glycogenes with relevant N-linked glycosylation, O-Linked glycosylation, glycosphingolipids in human HCC cell lines, orthotopic xenograft tumors and clinical cancer specimens.

The metastatic potential of HCC cell lines in our experiments were strengthening step by step. Hep3B, the non-metastatic cell line from ATCC, was established from a patient of 8-year-old black boy. Nevertheless, MHCC97L, MHCC97H and HCCLM3, all of them can metastasize, whose metastatic potential were increasing in general [@pone.0107941-Li4]. The original source of these cell lines was MHCC97 which derived from the LCI20 tumor line (male HCC) and their lung metastatic rate were 40%, 100% and 100%, respectively. The node rate of HCCLM3 was 60% [@pone.0107941-Tian1]. We found thirty-three differentially transcribed glycogenes by the Human Glycosylation RT^2^ Profiler PCR Array with differences greater than 2-fold (P≤0.05) as a criteria. A glycomics study using glycogene microarray which contained 115 genes by Kang et.al reported eighteen glycogenes were up-regulated in high metastatic potential HCCLM3 cell lines in comparison to Hep3B cell lines, while eleven glycogenes were down-regulated [@pone.0107941-Kang1]. Guo et.al's study using qRT-PCR for quantification found that six glycogenes *b3galt1*, *fut8*, *gal3st2*, *mgat5*, *st3gal5 and st6gal1* were overexpressed in MHCC97H cell lines compared with those in MHCC97L cell lines; conversely, five glycogenes, *b3gnt6*, *b3gnt7*, *galnt6*, *mgat3 and st8sia2* were down-regulated [@pone.0107941-Guo1]. However, Kang et.al only compared the high metastatic potential HCC cell lines HCCLM3 to non-metastasis cell lines Hep3B and Guo et.al only compared two metastasis cell lines (MHCC97L and MHCC97H). Comparisons both of them carried out were between two cell lines, while our results were more confident than theirs with four cell lines to be compared, and all of the differently transcribed glycogenes had been identificated in orthotopic xenograft tumors and validated in clinical cancer specimens. Kang et.al used glycogene microarray, by contrast, we used the PCR-Array. It was cheaper than by gene microarrays and its experimental conditions could be easily controlled [@pone.0107941-Kurokawa1]. In contrast with Guo et.al's result by qRT-PCR, our findings obtained more differentially transcribed genes. Additionally, apart from the glycogenes which have been reported previously like *mgat1*, *mgat5 and st3gal1*, some glycogenes such as "UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase" family members: *galnt3*, *galnt4*, *galnt11*, *galnt13*, and "mannosidase, α class" family members, for instance, *man1b1*, *man1c1*, *man2a2*, their different expressions were associated with HCC metastasis are the first reported. This research revealed that glycogenes which could generate and alter sialylated glycan structures or β-1, 6-GlcNAc branched N-Glycan were significantly up-regulated in the metastatic HCC cell lines and their orthotopic xenograft tumors. Sialic acids could prevent cell-cell interactions through charge repulsion effects [@pone.0107941-DallOlio1]. Tumor cell lines with more invasive ability expressed more heavily sialylated glycan structures. *mgat5* could advance tumor growth and metastasis by destructing the extracellular matrix or boost the production of angiogenic factors by a metal ion-dependent serine protease. *mgat5* could also promote tumor metastasis by catalyzing sugar chain which can change the function of angiogenic factors or by directly increasing the gene transcription of angiogenic factors [@pone.0107941-Qi1].

The qRT-PCR analysis of the transcribed glycogenes in the human HCC cell lines and their orthotopic xenograft tumors provided evidences of the same changing trends in statistics (P\<0.05) to support the analysis of PCR-array results. Nevertheless, we found that the respective fold-change value of comparison results within metastatic HCC cell lines and their orthotopic xenograft tumors had no obvious gradually change trend. It revealed that the transcriptional of glycogenes was highly related with metastasis no matter whether their metastatic potentials were high or low. Therefore, we suggested that our future studies about glycosyltransferases should more focus on comparison of whether these cells or orthotopic xenograft tumors were able to metastatic or not rather than the difference of their metastatic potentials.

The regulatory network of part of the differentially transcribed glycogenes was obtained by the IPA, and it included six types of relationship and nineteen upstream regulators. Aside from regulators, current data suggests that miRNA is related with the expressions of glycogenes. Human and rodents HCC cell lines were transfected with miR-122 and miR-34a and the result demonstrated that forced expression of these miRNAs was able to induce a decrease of *fut8* levels and also to affect core fucosylation of secreted proteins [@pone.0107941-Bernardi1]. The passenger strand miR-17-3p repressed expression of *galnt7*, which regulates metabolism of liver toxin galactosamine [@pone.0107941-Shan1]. Further analysis including glycogenes regulation may elucidate the changes of the expressions of glycogenes.

The validation in clinical cancer specimens showed some differences of the transcription levels of glycogenes in clinical tissue samples were not significant. It might be caused by the part of the differences among cell lines, orthotopic xenograft tumors and clinical tissue samples themselves. But it was important to note there were still a substantial part of glycogenes which were differentially transcribed between non-metastatic and metastatic tissues. This evidence suggested there might be some potential novel drug targets and biological markers to predict metastasis of HCC in the differentially transcribed genes. To validate the transcription levels of the remaining differentially transcribed glycogenes, further investigation is needed and this part of the work is undergoing. Moreover, it could not be neglected that our study is the first time to provide evidences in human HCC cell lines, orthotopic xenograft tumors and clinical tissue samples that the up-regulated of *gcnt3* and *mgat5b* were associated with HCC metastasis.

In summary, this study identified thirty-three differentially transcribed glycogenes by the Human Glycosylation RT^2^ Profiler PCR Array. A total of seven glycogenes, including *c1galt1*, *galnt3*, *gcnt3*, *man1a1*, *mgat4b*, *mgat5*, *mgat5b*, were further identified by qRT-PCR in HCC cell lines and their orthotopic xenograft tumors. All of these differentially transcribed glycogenes were analyzed by *K*-means and GO analysis, and were uploaded to the IPA database for regulatory network analysis. What was more, *galnt3*, *gcnt3*, *man1a1* and *mgat5b* were selected to further validation in clinical cancer specimens and this is the first report that the up-regulated of *gcnt3* and *mgat5b* were associated with HCC metastasis. The differentially transcribed glycogenes could be the potential targets for the novel drugs and might act as the potential biological markers to predict metastasis of HCC.
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